Fluoroquinolone resistance in Streptococcus pneumoniae: Area under the concentration-time curve/MIC ratio and resistance development with gatifloxacin, gemifloxacin, levofloxacin, and moxifloxacin

Antimicrobial Agents and Chemotherapy

Volumn 51, Issue 4, 2007, Pages 1315-1320

  LaPlante, Kerry L ^a,b,e   Rybak, Michael J ^a,b   Tsuji, Brian ^a,b,f   Lodise, Thomas P ^d   Kaatz, Glenn W ^a,c  

^a WAYNE STATE UNIVERSITY   (United States)

^b DETROIT RECEIVING HOSPITAL   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

^d ALBANY COLLEGE OF PHARMACY AND HEALTH SCIENCES   (United States)

^e UNIVERSITY OF RHODE ISLAND   (United States)

^f UNIVERSITY AT BUFFALO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DNA TOPOISOMERASE (ATP HYDROLYSING) A; DNA TOPOISOMERASE (ATP HYDROLYSING) B; GATIFLOXACIN; GEMIFLOXACIN; LEVOFLOXACIN; MOXIFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

ANTIBIOTIC RESISTANCE; AREA UNDER THE CURVE; ARTICLE; BACTERIAL GROWTH; BACTERIAL STRAIN; BACTERIUM ISOLATE; COLONY FORMING UNIT; DRUG HALF LIFE; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; SEQUENCE ANALYSIS; STREPTOCOCCUS PNEUMONIAE;

AREA UNDER CURVE; AZA COMPOUNDS; DRUG RESISTANCE, BACTERIAL; FLUOROQUINOLONES; MICROBIAL SENSITIVITY TESTS; NAPHTHYRIDINES; OFLOXACIN; PNEUMOCOCCAL INFECTIONS; QUINOLINES; STREPTOCOCCUS PNEUMONIAE;

EID: 34247101013     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.00646-06     Document Type: Article

References (32)

1. Allen, G. P., G. W. Kaatz, and M. J. Rybak. 2003. Activities of mutant prevention concentration-targeted moxifloxacin and levofloxacin against Streptococcus pneumoniae in an in vitro pharmacodynamic model. Antimicrob. Agents Chemother. 47:2606-2614.
2. Ambrose, P. G., D. M. Grasela, T. H. Grasela, J. Passarell, H. B. Mayer, and P. F. Pierce. 2001. Pharmacodynamics of fluoroquinolones against Streptococcus pneumoniae in patients with community-acquired respiratory tract infections. Antimicrob. Agents Chemother. 45:2793-2797.
3. Andersson, M. I., and A. P. MacGowan. 2003. Development of the quinolones. J. Antimicrob. Chemother. 51(Suppl. 1):1-11.
4. Andes, D., and W. A. Craig. 2002. Pharmacodynamics of the new fluoroquinolone gatifloxacin in murine thigh and lung infection models. Antimicrob. Agents Chemother. 46:1665-1670.
5. Bhavnani, S. M., J. P. Hammel, R. N. Jones, and P. G. Ambrose. 2005. Relationship between increased levofloxacin use and decreased susceptibility of Streptococcus pneumoniae in the United States. Diagn. Microbiol. Infect. Dis. 51:31-37.
6. 5a. Clinical and Laboratory Standards Institute. 2006. Performance standards for antimicrobial susceptibility testing, 16th informational supplement M100-S16. Clinical and Laboratory Standards Institute, Wayne, Pa.
7. Coyle, E. A., G. W. Kaatz, and M. J. Rybak. 2001. Activities of newer fluoroquinolones against ciprofloxacin-resistant Streptococcus pneumoniae. Antimicrob. Agents Chemother. 45:1654-1659.
8. Doern, G. V., and S. D. Brown. 2004. Antimicrobial susceptibility among community-acquired respiratory tract pathogens in the USA: data from PROTECT US 2000-01. J. Infect. 48:56-65.
9. Drusano, G. L., D. E. Johnson, M. Rosen, and H. C. Standiford. 1993. Pharmacodynamics of a fluoroquinolone antimicrobial agent in a neutropenic rat model of Pseudomonas sepsis. Antimicrob. Agents Chemother. 37:483-490.
10. Ferrero, L., B. Cameron, and J. Crouzet. 1995. Analysis of gyrA and grlA mutations in stepwise-selected ciprofloxacin- resistant mutants of Staphylococcus aureus. Antimicrob. Agents Chemother. 39:1554-1558.
11. Florea, N. R., P. R. Tessier, C. Zhang, C. H. Nightingale, and D. P. Nicolau. 2004. Pharmacodynamics of moxifloxacin and levofloxacin at simulated epithelial lining fluid drug concentrations against Streptococcus pneumoniae. Antimicrob. Agents Chemother. 48:1215-1221.
12. Fukuda, H., and K. Hiramatsu. 1999. Primary targets of fluoroquinolones in Streptococcus pneumoniae. Antimicrob. Agents Chemother. 43:410-412.
13. Garrison, M. W., J. A. Schimmels, and K. J. Madaras-Kelly. 2003. In vitro pharmacodynamic activity of gatifloxacin, gemifloxacin, moxifloxacin and levofloxacin against Streptococcus pneumoniae containing specific mutations in DNA gyrase and topoisomerase IV. Diagn. Microbiol. Infect. Dis. 47:587-593.
14. Gill, M. J., N. P. Brenwald, and R. Wise. 1999. Identification of an efflux pump gene, pmrA, associated with fluoroquinolone resistance in Streptococcus pneumoniae. Antimicrob. Agents Chemother. 43:187-189.
15. Jones, M. E., D. F. Sahm, N. Martin, S. Scheuring, P. Heisig, C. Thornsberry, K. Kohrer, and F. J. Schmitz. 2000. Prevalence of gyrA, gyrB, parC, and parE mutations in clinical isolates of Streptococcus pneumoniae with decreased susceptibilities to different fluoroquinolones and originating from worldwide surveillance studies during the 1997-1998 respiratory season. Antimicrob. Agents Chemother. 44:462-466.
16. Jones, R. N., and M. A. Pfaller. 2000. In vitro activity of newer fluoroquinolones for respiratory tract infections and emerging patterns of antimicrobial resistance: data from the SENTRY antimicrobial surveillance program. Clin. Infect. Dis. 31(Suppl. 2):S16-S23.
17. Kaatz, G. W., and S. M. Seo. 1997. Mechanisms of fluoroquinolone resistance in genetically related strains of Staphylococcus aureus. Antimicrob. Agents Chemother. 41:2733-2737.
18. Karchmer, A. W. 2004. Increased antibiotic resistance in respiratory tract pathogens: PROTEKT US-an update. Clin. Infect. Dis. 39(Suppl. 3):S142-S150.
19. Karlowsky, J. A., C. Thornsberry, M. E. Jones, A. T. Evangelista, I. A. Critchley, and D. F. Sahm. 2003. Factors associated with relative rates of antimicrobial resistance among Streptococcus pneumoniae in the United States: results from the TRUST Surveillance Program (1998-2002). Clin. Infect. Dis. 36:963-970.
20. Lim, S., D. Bast, A. McGeer, J. de Azavedo, and D. E. Low. 2003. Antimicrobial susceptibility breakpoints and first-step parC mutations in Streptococcus pneumoniae: redefining fluoroquinolone resistance. Emerg. Infect. Dis. 9:833-837.
21. Lu, T., X. Zhao, X. Li, A. Drlica-Wagner, J. Y. Wang, J. Domagala, and K. Drlica. 2001. Enhancement of fluoroquinolone activity by C-8 halogen and methoxy moieties: action against a gyrase resistance mutant of Mycobacterium smegmalis and a gyrase-topoisomerase IV double mutant of Staphylococcus aureus. Antimicrob. Agents Chemother. 45:2703-2709.
22. Neyfakh, A. A., C. M. Borsch, and G. W. Kaatz. 1993. Fluoroquinolone resistance protein NorA of Staphylococcus aureus is a multidrug efflux transporter. Antimicrob. Agents Chemother. 37:128-129.
23. Pan, X. S., J. Ambler, S. Mehtar, and L. M. Fisher. 1996. Involvement of topoisomerase IV and DNA gyrase as ciprofloxacin targets in Streptococcus pneumoniae. Antimicrob. Agents Chemother. 40:2321-2326.
24. Perichon, B., J. Tankovic, and P. Courvalin. 1997. Characterization of a mutation in the parE gene that confers fluoroquinolone resistance in Streptococcus pneumoniae. Antimicrob. Agents Chemother. 41:1166-1167.
25. Reinert, R. R., S. Reinert, M. van der Linden, M. Y. Cil, A. Al-Lahham, and P. Appelbaum. 2005. Antimicrobial susceptibility of Streptococcus pneumoniae in eight European countries from 2001 to 2003. Antimicrob. Agents Chemother. 49:2903-2913.
26. Saravolatz, L., O. Manzor, J. Pawlak, and B. Belian. 2005. Antimicrobial activity and a comparison of published pharmacodynamics of gemifloxacin and eight fluoroquinolones against Streptococcus pneumoniae. Int. J. Antimicrob. Agents 26:81-84.
27. Taba, H., and N. Kusano. 1998. Sparfloxacin resistance in clinical isolates of Streptococcus pneumoniae: involvement of multiple mutations in gyrA and parC genes. Antimicrob. Agents Chemother. 42:2193-2196.
28. Tang, P., K. Green, A. McGeer, et al. 2002. Abstr. 42nd Intersci. Conf. Antimicrob. Agents Chemother., San Diego, CA, abstr. C-1631.
29. Tankovic, J., B. Perichon, J. Duval, and P. Courvalin. 1996. Contribution of mutations in gyrA and parC genes to fluoroquinolone resistance of mutants of Streptococcus pneumoniae obtained in vivo and in vitro. Antimicrob. Agents Chemother. 40:2505-2510.
30. Thomson, C. J. 1999. The global epidemiology of resistance to ciprofloxacin and the changing nature of antibiotic resistance: a 10 year perspective. J. Antimicrob. Chemother. 43(Suppl. A):31-40.
31. Yague, G., J. E. Morris, X. S. Pan, K. A. Gould, and L. M. Fisher. 2002. Cleavable-complex formation by wild-type and quinolone-resistant Streptococcus pneumoniae type II topoisomerases mediated by gemifloxacin and other fluoroquinolones. Antimicrob. Agents Chemother. 46:413-419.
32. Zabinski, R. A., A. J. Larsson, K. J. Walker, S. S. Gilliland, and J. C. Rotschafer. 1993. Elimination of quinolone antibiotic carryover through use of antibiotic-removal beads. Antimicrob. Agents Chemother. 37:1377-1379.